Barclays Maintains Stryker at Overweight, Cuts Price Target to $365
Barclays maintained its Overweight rating on Stryker and lowered its price target to $365 from $375.
Barclays maintained its Overweight rating on Stryker and lowered its price target to $365 from $375.